Using Ruxolitinib to treat symptoms of essential thrombocythemia and polycythemia vera

A Phase 2 Study Of Ruxolitinib In Low-Risk Essential Thrombocythemia And Polycythemia Vera With Significant Symptom Burden

This study is testing if the drug Ruxolitinib can help reduce symptoms for people with low-risk essential thrombocythemia and polycythemia vera.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Massachusetts General Hospital (Academic / other)
• Drugs / interventions: ruxolitinib
• Locations: 4 sites (Boston, Massachusetts and 3 other locations)
• Trial ID: NCT04644211 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of Ruxolitinib in reducing symptoms for patients with low-risk essential thrombocythemia (ET) and polycythemia vera (PV). It is a multi-center, non-randomized, two-stage phase II trial involving approximately 60 participants who will receive Ruxolitinib for about six months. The study aims to determine if this FDA-approved drug for PV can also alleviate symptoms in ET patients, who currently have no approved treatment. Participants will undergo screening for eligibility and will have follow-up visits to monitor their response to the treatment.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with low-risk essential thrombocythemia or polycythemia vera who meet specific eligibility criteria.

Not a fit: Patients with high-risk essential thrombocythemia or those who do not meet the study's eligibility criteria may not benefit from this trial.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from the symptoms of essential thrombocythemia and polycythemia vera.

How similar studies have performed: While Ruxolitinib is FDA-approved for polycythemia vera, its use in essential thrombocythemia is novel and has not been extensively tested in this context.

Eligibility criteria

Inclusion Criteria:

* Patients who have been diagnosed with essential thrombocythemia or polycythemia vera by World Health Organization 2016 diagnostic criteria.
* Patients with essential thrombocythemia must be very low (no history of thrombosis, age \<60, and no JAK2 mutation), low (no history of thrombosis, age \<60, presence of JAK2 mutation), or intermediate risk (no history of thrombosis, age \>60, no JAK2 mutation) by IPSET criteria. Patients with polycythemia vera must be low risk (no history of thrombosis and age \<60) by NCCN guidelines.
* Patients with an MPN-SAF TSS (MPN-10) score \>10 AND at least one individual feature \>5 documented on a separate visit within 3 months prior to study registration, as documented in the clinical record or obtained by clinician. If not previously documented in the electronic medical record, participants must be blinded to purpose of MPN SAF TSS scoring for eligibility determination. Average daily MPN-SAF TSS (MPN-10) score must remain \>10 with any individual feature \>5 for the week-long baseline assessment prior to ruxolitinib initiation.
* Patients who have previously received or are receiving cytoreductive therapy (i.e. hydroxyurea, anagrelide, interferon) are eligible for the study if therapy was used for the indication of symptom control, or if therapy was used for pre-operative control of blood counts. If a subject is still receiving cytoreductive therapy at the time of screening and enrollment, there will be a wash-out period from prior cytoreductive therapy at least 7 days prior to ruxolitinib initiation.
* Age ≥18 years.
* ECOG performance status ≤2 (Karnofsky ≥60%)
* Participants must have adequate organ and marrow function as defined below:

  * leukocytes ≥3,000/mcL
  * absolute neutrophil count ≥1,500/mcL
  * platelets ≥100,000/mcL
  * total bilirubin ≤ institutional upper limit of normal (ULN)
  * AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
  * creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
* Participants with a prior or concurrent malignancy not receiving treatment for concurrent cancer diagnosis and/or prior concurrent malignancy within 5 years except for basal cell carcinoma or squamous cell carcinoma of the skin.
* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
* For participants with evidence of chronic human immunodeficiency virus (HIV) infection, they must be negative for HBV DNA, HCV RNA, or hepatitis B surface antigen (BsAg) on suppressive therapy, if indicated.
* Participants must be previously vaccinated with the Herpes Zoster (Shingles) vaccine or must be willing to start prophylactic Acyclovir 400 mg twice daily (BID) or suitable alternative for duration of treatment with ruxolitinib.
* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Essential thrombocythemia patients who are high risk by IPSET-R criteria (age \> 60 with JAK2 V617F mutation and/or history of thrombosis).1 Polycythemia vera patients who are high risk by NCCN guidelines (age \> 60 and/or history of thrombosis).
* Patients with \>5% blasts on baseline marrow exam or at any other time in peripheral blood
* Participants who are receiving any other investigational agents.
* Participants with a history of splenectomy. Participants may still be eligible after discussion with and approval by the Overall PI, however.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or excipients of ruxolitinib.
* Participants requiring any medications or substances that are strong inhibitors or 3A4 isozyme are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
* Participants with uncontrolled intercurrent illness.
* Participants with inadequate liver or renal function at screening as evidenced by lab values not meeting criteria
* Participants with psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women are excluded from this study because ruxolitinib is a Class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib.
* The effects of ruxolitinib on the developing human fetus are unknown. Pregnant women and subjects of childbearing potential who are unwilling to take appropriate precautions to avoid becoming pregnant or fathering a child are ineligible. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ruxolitinib administration.

Where this trial is running

Boston, Massachusetts and 3 other locations

• Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
• Beth-Israel Deaconess Medical Center — Boston, Massachusetts, United States (Not_yet_recruiting)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
• Massachusetts General North Shore Cancer Center — Danvers, Massachusetts, United States (Recruiting)

Study contacts

• Principal investigator: Gabriela Hobbs, MD — Massachusetts General Hospital
• Study coordinator: Gabriela Hobbs, MD

Conditions Essential Thrombocythemia; Polycythemia Vera; Sympton Burden